Industry
Medical - Devices
NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its principal products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, India, and internationally. NanoVibronix, Inc. was incorporated in 2003 and is based in Elmsford, New York.
Loading...
Open
0.65
Mkt cap
2.4M
Volume
41K
High
0.68
P/E Ratio
-0.52
52-wk high
1.52
Low
0.63
Div yield
N/A
52-wk low
0.46
Portfolio Pulse from Benzinga Newsdesk
April 09, 2024 | 12:55 pm
Portfolio Pulse from Benzinga Newsdesk
March 28, 2024 | 12:36 pm
Portfolio Pulse from Benzinga Newsdesk
January 25, 2024 | 4:14 pm
Portfolio Pulse from Benzinga Newsdesk
January 25, 2024 | 4:09 pm
Portfolio Pulse from Benzinga Newsdesk
December 04, 2023 | 2:05 pm
Portfolio Pulse from Benzinga Newsdesk
November 28, 2023 | 2:33 pm
Portfolio Pulse from Benzinga Newsdesk
November 21, 2023 | 1:34 pm
Portfolio Pulse from Benzinga Insights
November 20, 2023 | 9:31 pm
Portfolio Pulse from Benzinga Newsdesk
November 14, 2023 | 1:49 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.